Please use this identifier to cite or link to this item: https://hdl.handle.net/1/153
Title: Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: New insights
Authors: MacDougall, I.C.;Roger, Simon D ;De Francisco, Angel ;Goldsmith, David J A ;Schellekens, Huub ;Ebbers, Hans ;Jelkmann, Wolfgang ;London, Gérard ;Casadevall, Nicole ;Hörl, Walter H;Kemeny, David M ;Pollock, Carol 
Issue Date: Apr-2012
Source: Volume 81, Issue 8, pp. 727-732
Journal title: Kidney International
Abstract: Antibody-mediated pure red cell aplasia is a very rare but devastating condition affecting patients receiving treatment with erythropoiesis-stimulating agents. New cases continue to emerge, generally in clusters, consistent with an 'environmental' trigger to its pathogenesis. Defining the causes of antibody-mediated pure red cell aplasia is clearly of importance for patients with chronic kidney disease, but any developments in this area may also have relevance to other disease areas as therapeutic delivery of endogenous proteins rapidly increases. This review focuses on the current knowledge regarding the etiology of antibody-mediated pure red cell aplasia and the current approach to therapy.
Description: Open Access: http://www.nature.com/ki/journal/v81/n8/abs/ki2011500a.html
URI: https://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/153
DOI: 10.1038/ki.2011.500
Pubmed: http://www.ncbi.nlm.nih.gov/pubmed/22336988
ISSN: 00852538
Publicaton type: Journal Article
Keywords: Drug Therapy
Kidney Disease
Immunology
Appears in Collections:Renal Medicine

Show full item record

Page view(s)

10
checked on Feb 2, 2023

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.